Clinical Report: The Promise of TKIs
Overview
Tyrosine kinase inhibitors (TKIs) show potential as a new treatment for wet AMD and diabetic retinopathy, addressing the burden of frequent anti-VEGF injections. Current clinical trials are exploring various TKIs and their delivery methods to enhance treatment durability and efficacy.
Background
Neovascular age-related macular degeneration (nAMD) and diabetic retinopathy (DR) are significant causes of vision loss, with current treatments primarily relying on anti-VEGF injections. These therapies, while effective, require frequent administration and can lead to patient discontinuation due to associated burdens. The exploration of TKIs represents a promising avenue to improve treatment outcomes and reduce the frequency of interventions.
Data Highlights
No numerical data available in the source material.
Key Findings
- TKIs can inhibit multiple pathways involved in retinal diseases, potentially offering broader therapeutic effects compared to anti-VEGF agents.
- Current TKIs in clinical trials include AIV007, D-4517.2, and EYP-1901, each utilizing innovative delivery methods.
- D-4517.2 has shown significant reduction in neovascularization in animal models and is currently in a phase 2 trial for nAMD and DME.
- EYP-1901 has met non-inferiority endpoints compared to aflibercept in phase 2 trials, with fewer supplemental injections required.
- TKIs are not yet part of standard treatment guidelines but are being investigated for their potential to reduce treatment burden.
Clinical Implications
The development of TKIs may lead to more effective and durable treatment options for patients with nAMD and DR, potentially decreasing the frequency of necessary injections. Clinicians should stay informed about ongoing clinical trials and emerging data to better guide treatment decisions.
Conclusion
TKIs represent a promising advancement in the treatment landscape for retinal diseases, with ongoing research necessary to establish their role in clinical practice.
References
- Retinal Physician, 2025 -- Tyrosine Kinase Inhibitors in Retinal Exudative Diseases
- Retinal Physician, 2026 -- The Evolving TKI Pipeline
- AAO Age-Related Macular Degeneration Guideline Summary - Guideline Central
- EyePoint Pharmaceuticals, 2025 -- EYP-1901 Phase 2 Trial Results
- Ophthalmology Management, 2026 -- Axpaxli Shows Superiority Over Aflibercept in Phase 3 Trial
- Retinal Physician — The Evolving TKI Pipeline
- retinal physician — The Evolving TKI Pipeline
- AAO Age-Related Macular Degeneration Guideline Summary - Guideline Central
- https://eyepointpharma.com/wp-content/uploads/2025/01/HIEye2024_25012001.pdf
- Axpaxli Shows Superiority Over Aflibercept in Phase 3 Trial | Ophthalmology Management
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
